• Male

Dr. J.J. Molenaar MD PhD

Position: Postdoc
Main activities: Research
Specialisation: Targeted drug development
foto
Focus of research:

The targeted drug development group at the department of Oncogenomics aims at the identification and validation of new therapeutic interventions for pediatric neuroblastoma. A highly efficient pipeline covering the full spectrum of targeted drug development is currently functional. The process starts with the identification of new drug targets using high throughput analysis as Affymetrix mRNA profiling, aCGH, MIR profiling and recently also Whole Genome Sequencing. Potential new target genes are subsequently validated in neuroblastoma cell line systems using a variety of molecular genetic manipulation techniques. The most promising target genes are then inhibited using small molecule inhibitors in vitro and in vivo. Several new models are developed to consolidate this process. Tumor Initiating Cell lines are isolated from patient material to obtain representative tumor systems and new xenograft models are developed.
 

AMC themes: Oncology
Departments: Oncogenomics
Bate-Eya LT. Neuroblastoma: Crossing borders in targeted therapy. S.l.: s.n.; 2017. 233p. ISBN 978-94-6299-631-1 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Caron HN; copromotor(s): Molenaar JJ , Dolman MEM)
Bate-Eya LT, Gierman HJ, Ebus ME, Koster J, Caron HN, Versteeg R, Dolman MEM, Molenaar JJ, Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. EUR J CANCER 2017;75:63-72 [PubMed]
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, de Preter K, Molenaar J, Schramm A, Eilers M, van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson ADJ, Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. EXPERT OPIN DRUG DIS 2017;12 (8):801-811 [PubMed]
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E, p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. CLIN CANCER RES 2017;23 (21):6629-6639 [PubMed]
van Groningen T , Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N , Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R, Neuroblastoma is composed of two super-enhancer-associated differentiation states. NAT GENET 2017;49 (8):1261-1266 [PubMed]
Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, Le Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B, Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. ANTICANCER RES 2016;36 (2):599-609 [PubMed]
Bate-Eya LT, den Hartog IJM, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman MEM, High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. ONCOTARGET 2016;7 (19):27946-27958 [PubMed]
Dorneburg C, Goß AV, Fischer M, Roels F, Barth TFE, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C, γ-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. ONCOTARGET 2016;7 (39):62799-62813 [PubMed]
Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, Epple M, Kozlova D, Yoon S, Baek K, Vandesompele J, Eggert A, Schramm A, Schulte JH, miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. INT J CANCER 2015;136 (6):1308-1320 [PubMed]
Ariës IM, van den Dungen RE, Koudijs MJ, Cuppen E, Voest E, Molenaar JJ, Caron HN, Pieters R, den Boer ML, Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. HAEMATOLOGICA 2015;100 (4):e132-e136 [PubMed]
Beckers A, van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, de Preter K, Speleman F, MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. CANCER LETT 2015;366 (1):123-132 [PubMed]
Dolman MEM, Poon E, Ebus ME, den Hartog IJM, van Noesel CJM, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ, Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. CLIN CANCER RES 2015;21 (22):5100-5109 [PubMed]
Dolman MEM, van der Ploeg I, Koster J, Bate-Eya LT, Versteeg R, Caron HN, Molenaar JJ, DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLOS ONE 2015;10 (12):e0145744 [PubMed]
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TBK, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman MEM, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM, Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. NAT GENET 2015;47 (8):864-871 [PubMed]
Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F, Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. ONCOTARGET 2015;6 (21):18558-18576 [PubMed]
Spel L, Boelens JJ, van der Steen DM, Blokland NJG, van Noesel MM, Molenaar JJ, Heemskerk MHM, Boes M, Nierkens S, Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. ONCOTARGET 2015;6 (34):35770-35781 [PubMed]
Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GAM, Molenaar JJ, Versteeg R, TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. NAT GENET 2015;47 (12):1411-+ [PubMed]
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GAM, Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. J MOL DIAGN 2015;17 (1):43-52 [PubMed]
Bate-Eya LT, Ebus ME, Koster J, den Hartog IJM, Zwijnenburg DA, Schild L, van der Ploeg I, Dolman MEM, Caron HN, Versteeg R, Molenaar JJ, Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. EUR J CANCER 2014;50 (3):628-637 [PubMed]
Dolman MEM, den Hartog IJM, Molenaar JJ, Schellens JHM, Beijnen JH, Sparidans RW, Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. J PHARMACEUT BIOMED 2014;88:216-220 [PubMed]
Dolman MEM, den Hartog IJM, Molenaar JJ, Schellens JHM, Beijnen JH, Sparidans RW, Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. J PHARMACEUT BIOMED 2014;92:144-148 [PubMed]
Kloosterman WP, Koster J, Molenaar JJ, Prevalence and clinical implications of chromothripsis in cancer genomes. CURR OPIN ONCOL 2014;26 (1):64-72 [PubMed]
Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, González-Neira A, Pita G, Alonso MR, Wang Q, Bolla MK, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Neuhausen SL, Ziogas A, Clarke CA, Hopper JL, Dite GS, Apicella C, Southey MC, Chenevix-Trench G, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Bojesen SE, Nordestgaard BG, Flyger H, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Dunning AM, Shah M, Guénel P, Truong T, Sanchez M, Mulot C, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, Collée JM, Jager A, Cox A, Brock IW, Reed MWR, Devilee P, Tollenaar RAEM, Seynaeve C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Dumont M, Soucy P, Dörk T, Bogdanova NV, Hamann U, Försti A, Rüdiger T, Ulmer HU, Fasching PA, Häberle L, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Radice P, Peterlongo P, Peissel B, Mariani P, Giles GG, Severi G, Baglietto L, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Burwinkel B, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Alnæs GG, Kristensen V, Børresen-Dale AL, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Schmidt MK, Broeks A, Verhoef S , Rutgers EJ, Brauch H, Brüning T, Ko YD, Couch FJ, Toland AE, Yannoukakos D, Pharoah PDP, Hall P, Benítez J, Malats N, Easton DF [Contributors: Lo WY, Justenhoven C, Baisch C, Fischer HP, Pesch B, Rabstein S, Lotz A, Harth V, Heikkinen T, Erkkilä I, Aaltonen K, von Smitten K, Antonenkova N, Hillemanns P, Christiansen H, Myöhänen E, Kemiläinen H, Thorne H, Niedermayr E, Bowtell D, Chenevix-Trench G, deFazio A, Gertig D, Green A, Webb P, Parsons P, Hayward N, Whiteman D, Peuteman G, Smeets D, van Brussel T, Corthouts K, Slanger T, Mutschelknauss E, Salazar R, Behrens S, Birr R, Busch W, Eilber U, Kaspereit B, Knese N, Smit K, Manoukian S, Zaffaroni D, Barile M, Feroce I, Bonanni B, Goldberg M, Tranchant M, Valois MF, Turgeon A, Heguy L, Otsukka M, Mononen K, Selander T, Weerasooriya N, Krol-Warmerdam E, Molenaar J, Blom J, Brinton L, Szeszenia-Dabrowska N, Peplonska B, Zatonski W, Chao P, Stagner M, Bos P, Blom J, Crepin E, Nieuwlaat A, Heemskerk A, Higham S, Cross S, Cramp H, Connley D, Pilarski R]] , A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. HUM MOL GENET 2014;23 (7):1934-1946 [PubMed]
Schulte JH, Lindner S, Bohrer A, Maurer J, de Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A, MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. ONCOGENE 2013;32 (8):1059-1065 [PubMed]
Lamers F, Schild L, den Hartog IJM, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ, Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. EUR J CANCER 2012;48 (16):3093-3103 [PubMed]
Lamers F, Schild L, Koster J, Speleman F, Øra I, Westerhout EM, van Sluis P, Versteeg R, Caron HN, Molenaar JJ, Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC CANCER 2012;12 (1):285 [PubMed]
Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ, Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. EUR J CANCER 2012;48 (5):763-771 [PubMed]
Lamers SGM. New therapeutic targets in the intrinsic apoptotic pathway in neuroblastoma. s.l.: s.n.; 2012. 135p. ISBN 9789462030404 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R, Caron HN; copromotor(s): Molenaar JJ)
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. NAT GENET 2012;44 (11):1199-1206 [PubMed]
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R, Copy Number Defects of G1-Cell Cycle Genes in Neuroblastoma are Frequent and Correlate with High Expression of E2F Target Genes and a Poor Prognosis. GENE CHROMOSOME CANC 2012;51 (1):10-19 [PubMed]
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. NATURE 2012;483 (7391):589-U107 [PubMed]
Rausch T, Jones DTW, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO, Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. CELL 2012;148 (1-2):59-71 [PubMed]
Santo EE , Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ, Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. ONCOGENE 2012;31 (12):1571-1581 [PubMed]
Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans MEC, Molenaar JJ, van Nes J, Versteeg R, Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. P NATL ACAD SCI USA 2012;109 (47):19190-19195 [PubMed]
de Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, van Roy N, Speleman F, Vandesompele J, miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. CLIN CANCER RES 2011;17 (24):7684-7692 [PubMed]
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ, Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. ENDOCR-RELAT CANCER 2011;18 (6):657-668 [PubMed]
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL, Dissection of the Oncogenic MYCN Transcriptional Network Reveals a Large Set of Clinically Relevant Cell Cycle Genes as Drivers of Neuroblastoma Tumorigenesis. MOL CARCINOGEN 2011;50 (6):403-411 [PubMed]
Verissimo CS, Molenaar JJ, Fitzsimons CP, Vreugdenhil E, Neuroblastoma therapy: what is in the pipeline?. ENDOCR-RELAT CANCER 2011;18 (6):R213-R231 [PubMed]
Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Ora I, Eva A, Puppo M, Varesio L, A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. MOL CANCER 2010;9 (1):185 [PubMed]
Molenaar JJ , Ebus ME, Koster J, Santo E, Geerts D, Versteeg R, Caron HN, Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. ONCOGENE 2010;29 (18):2739-2745 [PubMed]
Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen E, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. ENDOCR-RELAT CANCER 2010;17 (2):399-414 [PubMed]
Molenaar JJ. The cell cycle in neuroblastoma. From genomic aberrations to targeted intervention. s.l.: s.n.; 2009. 132p. ISBN 9789090245003 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Caron HN, Versteeg R; copromotor(s): )
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN, Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. P NATL ACAD SCI USA 2009;106 (31):12968-12973 [PubMed]
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R, Caron HN, Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. CANCER RES 2008;68 (8):2599-2609 [PubMed]
Michels E, Vandesompele J, de Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, de Paepe A, Versteeg R, Eggert A, Laureys G, van Roy N, Speleman F, ArrayCGH-based classification of neuroblastoma into genomic subgroups. GENE CHROMOSOME CANC 2007;46 (12):1098-1108 [PubMed]
Onland W, Molenaar JJ , Leguit RJ, Van Nierop JC , Noorduyn LA, van Rijn RR, Geukers VGM, Pulmonary interstitial glycogenosis in identical twins. PEDIATR PULM 2005;40 (4):362-366 [PubMed]
Molenaar J. Treatment decision support for early breast cancer patients. S.l.: s.n.; 2004. 167p. ISBN 90-9018354-X [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haes JCJM; copromotor(s): Sprangers MAG)
Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN, Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. GENE CHROMOSOME CANC 2003;36 (3):242-249 [PubMed]
Molenaar JJ , Gérard B, Chambon-Pautas C, Cavé H, Duval M, Vilmer E, Grandchamp B, Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. BLOOD 1998;92 (1):230-233 [PubMed]
Key publications

Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. NAT GENET 2012;44 (11):1199-1206 [PubMed]
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. NATURE 2012;483 (7391):589-U107 [PubMed]
Rausch T, Jones DTW, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO, Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. CELL 2012;148 (1-2):59-71 [PubMed]
Santo EE , Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ, Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. ONCOGENE 2012;31 (12):1571-1581 [PubMed]
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN, Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. P NATL ACAD SCI USA 2009;106 (31):12968-12973 [PubMed]


All Publications

Research programmes

Dr. J.J. Molenaar MD PhD (Targeted drug development in neuroblastoma)

Faculty
Dr. J.J. Molenaar MD PhD

PhD Students
T.F. Eleveld MSc
A. Hakkert

Others
M.E. Ebus
I. den Hartog
Dr. S.G.M. Lamers
I. van der Ploeg
G.G. Schild

Prof. dr. H.N. Caron MD PhD (Paediatric Oncology; biology and clinical)

Other research related activities
  • None reported
Current research funding
  • Stichting KIKA